- Report
- May 2025
- 188 Pages
Global
From €3168EUR$3,545USD£2,762GBP
€3520EUR$3,939USD£3,069GBP
- Report
- August 2025
- 194 Pages
Global
From €5228EUR$5,850USD£4,557GBP
- Report
- May 2025
- 124 Pages
Global
From €4245EUR$4,750USD£3,700GBP
- Report
- March 2025
- 150 Pages
Global
From €3441EUR$3,850USD£2,999GBP
€4335EUR$4,850USD£3,778GBP
- Report
- June 2025
- 400 Pages
Global
From €4423EUR$4,949USD£3,855GBP
- Report
- January 2021
- 120 Pages
Global
From €2234EUR$2,500USD£1,948GBP
- Report
- March 2023
- 113 Pages
Global
From €4022EUR$4,500USD£3,506GBP
- Report
- February 2024
- 131 Pages
Global
From €4245EUR$4,750USD£3,700GBP
- Report
- February 2024
- 148 Pages
Global
From €4245EUR$4,750USD£3,700GBP
- Report
- October 2023
- 152 Pages
Global
From €3977EUR$4,450USD£3,467GBP
- Report
- October 2023
- 152 Pages
Global
From €3977EUR$4,450USD£3,467GBP
- Report
- October 2022
- 65 Pages
Global
From €3530EUR$3,950USD£3,077GBP
- Report
- August 2024
- 99 Pages
Global
From €3500EUR$4,195USD£3,157GBP
- Report
- November 2021
- 802 Pages
Global
From €4469EUR$5,000USD£3,895GBP
- Book
- August 2023
Global

Oncolytic Virotherapy is a form of cancer treatment that uses genetically modified viruses to target and destroy cancer cells. It is a form of gene therapy, as the viruses are modified to carry therapeutic genes that can be used to treat cancer. The viruses are designed to specifically target cancer cells, while leaving healthy cells unharmed. This form of therapy has been used to treat a variety of cancers, including melanoma, breast cancer, and lung cancer.
Oncolytic Virotherapy has the potential to be a more effective form of cancer treatment than traditional treatments, such as chemotherapy and radiation. It is also less invasive and has fewer side effects. Additionally, it can be used in combination with other treatments, such as immunotherapy, to further enhance its effectiveness.
The Oncolytic Virotherapy market is growing rapidly, as more companies are investing in the development of new treatments. Companies such as Amgen, Merck, and Pfizer are leading the way in the development of new treatments. Other companies, such as Oncolytics Biotech, ImmunoVaccine, and Vyriad, are also investing in the development of new treatments. Show Less Read more